期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 64, 期 3, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.02177-19
关键词
CPE; CRE; Enterobacterales; Enterobacteriaceae; HAP; Pseudomonas aeruginosa; VAP; carbapenemase; hospital-acquired pneumonia; ventilator-acquired pneumonia
资金
- Melinta Therapeutics, Inc.
Meropenem-vaborbactam is approved to treat hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), in Europe. Meropenem-vaborbactam activity was evaluated against 3,193 Pseudomonas aeruginosa and 4,790 Enterobacterales isolates causing pneumonia, including VAP, in hospitalized patients in the United States. Susceptibility testing was performed by using the broth microdilution method, and all carbapenem-resistant isolates were submitted for whole-genome sequencing. Meropenem-vaborbactam exhibited almost complete activity against Enterobacterales (>99.9% susceptible), including carbapenem-resistant Enterobacterales (CRE), and was also very active against P. aeruginosa isolates (89.5% susceptible).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据